PATHOPHYSIOLOGY OF COVID-19 ASSOCIATED WITH ACUTE KIDNEY INJURY
Keywords:
Covid-19, renal pathology, acute kidney injury, pathogenesis, IL6Abstract
To this day, the new respiratory infectious disease known as coronavirus disease 2019 (COVID-19) has been responsible for the deaths of over 630,000 individuals and the infection of around 15,000,000 people across the globe. This disease was caused by a new strain of zoonotic coronavirus named severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). It was first discovered in Wuhan, China, in December 2019. Most of the patients who passed away had pre-existing conditions; more than twenty percent of them had chronic kidney disease (CKD). In addition, even though SARS-CoV-2 infection is primarily characterized by diffuse alveolar damage and severe respiratory failure, acute kidney injury (AKI) has developed in a significant proportion of cases. It has been demonstrated that acute kidney injury (AKI) is linked to a more dismal prognosis; hence, we believe that the impact of SARS-CoV-2 on the kidney ought to be explored. The pathogenesis of covid 19, the pathophysiology of covid 19 acute kidney injury (AKI), the mechanisms of renal entry-kidney injury, and the clinical aspects of acute kidney injury (AKI) are the topics that are discussed in this article.
References
1. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708-20.
2. Okab HF, Salih MB, Jarulla BA. Immunopathy of COVID-19 Patients without Chronic Disease: Proinflammatory and Anti-Inflammatory Cytokines Attributable to Disease Severity.
3. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney international. 2020; 97(5):829-38.
4. Cheng Y, Luo R, Wang X, Wang K, Zhang N, Zhang M, et al. The incidence, risk factors, and prognosis of acute kidney injury in adult patients with coronavirus disease 2019. Clinical journal of the American Society of Nephrology: CJASN. 2020; 15(10):1394.
5. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney international. 2020; 98(1):209-18.
6. Mohamed MM, Lukitsch I, Torres-Ortiz AE, Walker JB, Varghese V, Hernandez-Arroyo CF, et al. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans. Kidney360. 2020;1(7):614.
7. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The lancet. 2020; 395(10239):1763-70.
8. Ng JH, Hirsch JS, Hazzan A, Wanchoo R, Shah HH, Malieckal DA, et al. Outcomes among patients hospitalized with COVID-19 and acute kidney injury. American Journal of Kidney Diseases. 2021; 77(2):204-15. e1.
9. Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. Journal of the American Society of Nephrology: JASN. 2021;32(1):161.
10. Carlson N, Nelveg‐Kristensen KE, Freese Ballegaard E, Feldt‐Rasmussen B, Hornum M, Kamper AL, et al. Increased vulnerability to Covid‐19 in chronic kidney disease. Journal of internal medicine. 2021;290(1):166-78.
11. Fu EL, Janse RJ, de Jong Y, van der Endt VH, Milders J, van der Willik EM, et al. Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. Clinical kidney journal. 2020;13(4):550-63.
12. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020;579(7798):270-3.
13. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-4.
14. Okab HF, Salih MB, Jarulla BA. Evaluation of CXCL 10 and IL-10 in COVID-19 pneumonia. Pneumologia.;71(4):175-80.
15. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. jama. 2020;323(11):1061-9.
16. van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, et al. COVID‐19: immunopathology, pathophysiological mechanisms, and treatment options. The Journal of pathology. 2021;254(4):307-31.
17. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging microbes & infections. 2020;9(1):382-5.
18. Cao X. COVID-19: immunopathology and its implications for therapy. Nature reviews immunology. 2020; 20(5):269-70.
19. Arabi YM, Murthy S, Webb S. COVID-19: a novel coronavirus and a novel challenge for critical care. Intensive care medicine. 2020;46:833-6.
20. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet. 2020;395(10224):565-74.
21. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9.
22. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. bmj. 2020;368.
23. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. Journal of virology. 2020;94(5):10.1128/jvi. 02015-19.
24. McBride R, Fielding BC. The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis. Viruses. 2012;4(11):2902-23.
25. Cao J, Tu W-J, Cheng W, Yu L, Liu Y-K, Hu X, et al. Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. Clinical Infectious Diseases. 2020;71(15):748-55.
26. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nature Reviews Immunology. 2014;14(5):315-28.
27. van der Poll T, Opal SM. Host–pathogen interactions in sepsis. The Lancet infectious diseases. 2008;8(1):32-43.
28. Liu X, Chen Y, Tang W, Zhang L, Chen W, Yan Z, et al. Single-cell transcriptome analysis of the novel coronavirus (SARS-CoV-2) associated gene ACE2 expression in normal and non-obstructive azoospermia (NOA) human male testes. Science China Life Sciences. 2020;63:1006-15.
29. Chen Q-L, Li J-Q, Xiang Z-D, Lang Y, Guo G-J, Liu Z-H. Localization of cell receptor-related genes of SARS-CoV-2 in the kidney through single-cell transcriptome analysis. Kidney Diseases. 2020;6(4):258-70.
30. Yoshikawa T, Hill T, Li K, Peters CJ, Tseng C-TK. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. Journal of virology. 2009;83(7):3039-48.
31. Lei Z, Cao H, Jie Y, Huang Z, Guo X, Chen J, et al. A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China. Travel medicine and infectious disease. 2020;35:101664.
32. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in hospitalized patients with COVID-19. Journal of the American Society of Nephrology. 2021;32(1):151-60.
33. Yang D, Xiao Y, Chen J, Chen Y, Luo P, Liu Q, et al. COVID-19 and chronic renal disease: clinical characteristics and prognosis. QJM: An International Journal of Medicine. 2020;113(11):799-805.
34. Li G, Ge Y, Sun Z, Luo S, Wang W, Zhou C, et al. Correlation Study of Chest CT Features of Severe/Critical type COVID-19 with Early Renal Damage and Clinical Prognosis. 2020.
35. Wang M, Xiong H, Chen H, Li Q, Ruan XZ. Renal injury by SARS-CoV-2 infection: a systematic review. Kidney Diseases. 2021;7(2):100-10.
36. Hamming I, Timens W, Bulthuis M, Lely A, Navis Gv, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2004; 203(2):631-7.
37. Asehnoune K, Villadangos J, Hotchkiss R. Understanding host–pathogen interaction. Intensive care medicine. 2016; 42:2084-6.
38. Streicher F, Jouvenet N. Stimulation of innate immunity by host and viral RNAs. Trends in Immunology. 2019; 40(12):1134-48.
39. Zhou J, Chu H, Li C, Wong BH-Y, Cheng Z-S, Poon VK-M, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. The Journal of infectious diseases. 2014; 209(9):1331-42.
40. Faour WH, Choaib A, Issa E, Choueiry FE, Shbaklo K, Alhajj M, et al. Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. Inflammation Research. 2022:1-18.
41. To K, Lo AW. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS‐CoV) and its putative receptor, angiotensin‐converting enzyme 2 (ACE2). The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2004; 203(3):740-3.
42. Chen Y-T, Shao S-C, Hsu C-K, Wu I-W, Hung M-J, Chen Y-C. Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis. Critical Care. 2020;24:1-4.
43. Zahid U, Ramachandran P, Spitalewitz S, Alasadi L, Chakraborti A, Azhar M, et al. Acute kidney injury in COVID-19 patients: an inner city hospital experience and policy implications. American journal of nephrology. 2020; 51(10):786-96.
44. Sabaghian T, Kharazmi AB, Ansari A, Omidi F, Kazemi SN, Hajikhani B, et al. COVID-19 and acute kidney injury: a systematic review. Frontiers in medicine. 2022; 9:705908.
45. Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in critically ill patients with COVID-19. Intensive care medicine. 2020; 46:1339-48.
46. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview. European journal of pharmacology. 2020; 889:173644.
47. Menéndez JC. Approaches to the potential therapy of COVID-19: a general overview from the medicinal chemistry perspective. Molecules. 2022;27(3):658.
48. Lee C, Choi WJ. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. Archives of pharmacal research. 2021;44(1):99-116.
49. Khalili M, Chegeni M, Javadi S, Farokhnia M, Sharifi H, Karamouzian M. Therapeutic interventions for COVID-19: a living overview of reviews. Therapeutic advances in respiratory disease. 2020; 14:1753466620976021.
50. Das G, Ghosh S, Garg S, Ghosh S, Jana A, Samat R, et al. An overview of key potential therapeutic strategies for combat in the COVID-19 battle. RSC advances. 2020;10(47):28243-66.
51. Kumari M, Lu R-M, Li M-C, Huang J-L, Hsu F-F, Ko S-H, et al. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. Journal of biomedical science. 2022; 29(1):68.
52. Li G, Hilgenfeld R, and Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nature Reviews Drug Discovery. 2023;22(6):449-75.
53. Shi Y, Wang G, Cai X-p, Deng J-w, Zheng L, Zhu H-h, et al. An overview of COVID-19. Journal of Zhejiang University Science B. 2020; 21(5):343.
